Literature DB >> 20553528

Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11.

Vincent R Bonagura1, Lynda J Hatam, David W Rosenthal, James A de Voti, Fung Lam, Bettie M Steinberg, Allan L Abramson.   

Abstract

Recurrent respiratory papillomatosis (RRP) is a rare disease of the larynx caused by infection with human papillomaviruses (HPV) -6 or -11, associated with significant morbidity and on occasion mortality. Here we summarize our current understanding of the permissive adaptive and innate responses made by patients with RRP that support chronic HPV infection and prevent immune clearance of these viruses. Furthermore, we provide new evidence of T(H)2-like polarization in papillomas and blood of patients with RRP, restricted CD4 and CD8 Vbeta repertoires, the effect of HPV-11 early protein E6 on T-cell alloreactivity, enriched Langerhans cell presence in papillomas, and evidence that natural killer cells are dysfunctional in RRP. We review the immunogenetic mechanisms that regulate the dysfunctional responses made by patients with RRP in response to HPV infection of the upper airway. In addition, we are identifying T-cell epitopes on HPV-11 early proteins, in the context of human leukocyte antigen (HLA) class II alleles enriched in RRP that should help generate a therapeutic vaccine. Taken together, RRP is a complex, multigene disease manifesting as a tissue and HPV-specific, immune deficiency that prevents effective clearance and/or control of HPV-6 and -11 infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20553528      PMCID: PMC2909665          DOI: 10.1111/j.1600-0463.2010.02617.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  87 in total

1.  Persistence and expression of human papillomavirus during interferon therapy.

Authors:  B M Steinberg; T Gallagher; M Stoler; A L Abramson
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1988-01

2.  Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up.

Authors:  Valentin Gerein; Eugen Rastorguev; Johann Gerein; Peter Jecker; Herbert Pfister
Journal:  Ann Otol Rhinol Laryngol       Date:  2005-06       Impact factor: 1.547

3.  Cloning and expression of a novel variant of human interferon-gamma cDNA.

Authors:  T Nishi; T Fujita; C Nishi-Takaoka; A Saito; T Matsumoto; M Sato; T Oka; S Itoh; Y K Yip; J Vilcek
Journal:  J Biochem       Date:  1985-01       Impact factor: 3.387

4.  Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens.

Authors:  M Nakagawa; D P Stites; S Patel; S Farhat; M Scott; N K Hills; J M Palefsky; A B Moscicki
Journal:  J Infect Dis       Date:  2000-07-28       Impact factor: 5.226

5.  Polymorphism of transporter associated with antigen presentation 1 as a potential determinant for severity of disease in recurrent respiratory papillomatosis caused by human papillomavirus types 6 and 11.

Authors:  Andrea Vambutas; Vincent R Bonagura; Elaine F Reed; Allan L Abramson; Virginia Mullooly; James DeVoti; David W Gjertson; Bettie M Steinberg
Journal:  J Infect Dis       Date:  2004-02-16       Impact factor: 5.226

Review 6.  Human papilloma viruses and cancer in the post-vaccine era.

Authors:  E Galani; C Christodoulou
Journal:  Clin Microbiol Infect       Date:  2009-11       Impact factor: 8.067

7.  Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.

Authors:  D G Alleva; C J Burger; K D Elgert
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

8.  Clinical effects of photodynamic therapy on recurrent laryngeal papillomas.

Authors:  A L Abramson; M J Shikowitz; V M Mullooly; B M Steinberg; C A Amella; H R Rothstein
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1992-01

9.  Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial.

Authors:  G B Healy; R D Gelber; A L Trowbridge; K M Grundfast; R J Ruben; K N Price
Journal:  N Engl J Med       Date:  1988-08-18       Impact factor: 91.245

10.  Enriched HLA-DQ3 phenotype and decreased class I major histocompatibility complex antigen expression in recurrent respiratory papillomatosis.

Authors:  V R Bonagura; F P Siegal; A L Abramson; F Santiago-Schwarz; M E O'Reilly; K Shah; D Drake; B M Steinberg
Journal:  Clin Diagn Lab Immunol       Date:  1994-05
View more
  50 in total

1.  Decreased Langerhans cell responses to IL-36γ: altered innate immunity in patients with recurrent respiratory papillomatosis.

Authors:  James DeVoti; Lynda Hatam; Alexandra Lucs; Ali Afzal; Allan Abramson; Bettie Steinberg; Vincent Bonagura
Journal:  Mol Med       Date:  2014-08-28       Impact factor: 6.354

2.  Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis.

Authors:  Magdalena Chirilă; Sorana D Bolboacă
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05       Impact factor: 2.503

3.  Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes.

Authors:  Shiwen Peng; Austin Mattox; Simon R Best; Anca M Barbu; James A Burns; Belinda Akpeng; Jessica Jeang; Benjamin Yang; Eiichi Ishida; Chien-Fu Hung; Tzyy-Choou Wu; Sara I Pai
Journal:  Cancer Immunol Immunother       Date:  2016-01-13       Impact factor: 6.968

Review 4.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

5.  Genetic dysregulation in recurrent respiratory papillomatosis.

Authors:  Regina Rodman; Simukayi Mutasa; Crystal Dupuis; Heidi Spratt; Michael Underbrink
Journal:  Laryngoscope       Date:  2014-03-11       Impact factor: 3.325

6.  The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.

Authors:  Julie Ahn; Justin A Bishop; Richard B S Roden; Clint T Allen; Simon R A Best
Journal:  Laryngoscope       Date:  2017-09-22       Impact factor: 3.325

7.  Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis.

Authors:  Scott B Drutman; Filomeen Haerynck; Franklin L Zhong; David Hum; Nicholas J Hernandez; Serkan Belkaya; Franck Rapaport; Sarah Jill de Jong; David Creytens; Simon J Tavernier; Katrien Bonte; Sofie De Schepper; Jutte van der Werff Ten Bosch; Lazaro Lorenzo-Diaz; Andy Wullaert; Xavier Bossuyt; Gérard Orth; Vincent R Bonagura; Vivien Béziat; Laurent Abel; Emmanuelle Jouanguy; Bruno Reversade; Jean-Laurent Casanova
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

Review 8.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

Review 9.  Cytotoxic potential of decidual NK cells and CD8+ T cells awakened by infections.

Authors:  Ângela C Crespo; Anita van der Zwan; João Ramalho-Santos; Jack L Strominger; Tamara Tilburgs
Journal:  J Reprod Immunol       Date:  2016-08-02       Impact factor: 4.054

10.  Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis.

Authors:  Irena Hočevar-Boltežar; Mojca Matičič; Maja Sereg-Bahar; Nina Gale; Mario Poljak; Boštjan Kocjan; Miha Zargi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-26       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.